Tags

Type your tag names separated by a space and hit enter

Polycystic ovary syndrome has no independent effect on vascular, inflammatory or thrombotic markers when matched for obesity.

Abstract

INTRODUCTION

Previous studies investigating cardiovascular (CV) risk in obese women with polycystic ovary syndrome (PCOS) have been potentially confounded by not adequately accounting for body weight.

OBJECTIVE

To assess if PCOS increases CV risk independently in young obese women by examining carotid intima-media wall thickness (cIMT) and platelet function.

DESIGN

A case-control study comparing women with PCOS (n = 21) to age (32·8 ± 7·2 vs 33·5 ± 6·7 years), and weight (100·9 ± 16·7 vs 99·3 ± 14·7 kg)-matched controls (n = 19). Platelet function was examined by flow cytometry, clot structure and fibrinolysis by turbidimetric assays and endothelial function by ELISA and post ischaemic reactive hyperaemia.

RESULTS

The PCOS group had higher testosterone 1·2 ± 0·3 vs 0·9 ± 0·3 nmol/l (P = 0·01), HOMA-IR 2·5 ± 1·7 vs 1·7 ± 1·0 (P = 0·08), impaired glucose regulation 33·3% vs 5·3% (P = 0·02), and urinary isoprostane 16·0 ± 4·4 vs 11·8 ± 7·1 ng/ml (P = 0·04) compared to controls. Mean cIMT 0·5 ± 0·05 vs 0·48 ± 0·06 mm (P = 0·36), and basal platelet surface expression (percentage of positive cells) of P-selectin 0·52 ± 0·3 vs 0·43 ± 0·23 (P = 0·40) and fibrinogen binding 0·97 ± 0·4 vs 0·83 ± 0·3 (P = 0·48) did not significantly differ between the PCOS and control groups respectively. Furthermore, platelets sensitivity to stimulation with adenosine-5'-diphosphate or inhibition with prostacyclin, clot structure and fibrinolytic efficiency ex vivo, endothelial reactive hyperaemic index (RHI), inflammation (hsCRP) and adhesion markers (sE-selectin, sP-selectin, sVCAM-1 and sICAM-1) were not significantly different between the two groups.

CONCLUSIONS

PCOS appeared not to independently increase atherothrombotic risk when matched for obesity. It is likely that any excess CV risk in young obese women with PCOS can either be attributed to obesity or is not yet apparent at this early stage of the condition.

Links

  • Publisher Full Text
  • Authors+Show Affiliations

    ,

    Academic Endocrinology, Diabetes and Metabolism, Hull York Medical School, Hull, UK. hassan.kahal@hyms.ac.uk

    , , , , , , , , ,

    Source

    Clinical endocrinology 79:2 2013 Aug pg 252-8

    MeSH

    Adult
    Blood Platelets
    Cardiovascular Diseases
    Carotid Intima-Media Thickness
    Endothelium, Vascular
    Female
    Humans
    Insulin Resistance
    Isoprostanes
    Obesity
    Platelet Activation
    Polycystic Ovary Syndrome
    Risk Factors

    Pub Type(s)

    Journal Article

    Language

    eng

    PubMed ID

    23278130

    Citation

    Kahal, H, et al. "Polycystic Ovary Syndrome Has No Independent Effect On Vascular, Inflammatory or Thrombotic Markers when Matched for Obesity." Clinical Endocrinology, vol. 79, no. 2, 2013, pp. 252-8.
    Kahal H, Aburima A, Ungvari T, et al. Polycystic ovary syndrome has no independent effect on vascular, inflammatory or thrombotic markers when matched for obesity. Clin Endocrinol (Oxf). 2013;79(2):252-8.
    Kahal, H., Aburima, A., Ungvari, T., Rigby, A. S., Dawson, A. J., Coady, A. M., ... Atkin, S. L. (2013). Polycystic ovary syndrome has no independent effect on vascular, inflammatory or thrombotic markers when matched for obesity. Clinical Endocrinology, 79(2), pp. 252-8. doi:10.1111/cen.12137.
    Kahal H, et al. Polycystic Ovary Syndrome Has No Independent Effect On Vascular, Inflammatory or Thrombotic Markers when Matched for Obesity. Clin Endocrinol (Oxf). 2013;79(2):252-8. PubMed PMID: 23278130.
    * Article titles in AMA citation format should be in sentence-case
    TY - JOUR T1 - Polycystic ovary syndrome has no independent effect on vascular, inflammatory or thrombotic markers when matched for obesity. AU - Kahal,H, AU - Aburima,A, AU - Ungvari,T, AU - Rigby,A S, AU - Dawson,A J, AU - Coady,A M, AU - Vince,R V, AU - Ajjan,R A, AU - Kilpatrick,E S, AU - Naseem,K M, AU - Atkin,S L, Y1 - 2013/05/11/ PY - 2012/10/08/received PY - 2012/12/14/revised PY - 2012/12/18/revised PY - 2012/12/19/accepted PY - 2013/1/3/entrez PY - 2013/1/3/pubmed PY - 2014/1/28/medline SP - 252 EP - 8 JF - Clinical endocrinology JO - Clin. Endocrinol. (Oxf) VL - 79 IS - 2 N2 - INTRODUCTION: Previous studies investigating cardiovascular (CV) risk in obese women with polycystic ovary syndrome (PCOS) have been potentially confounded by not adequately accounting for body weight. OBJECTIVE: To assess if PCOS increases CV risk independently in young obese women by examining carotid intima-media wall thickness (cIMT) and platelet function. DESIGN: A case-control study comparing women with PCOS (n = 21) to age (32·8 ± 7·2 vs 33·5 ± 6·7 years), and weight (100·9 ± 16·7 vs 99·3 ± 14·7 kg)-matched controls (n = 19). Platelet function was examined by flow cytometry, clot structure and fibrinolysis by turbidimetric assays and endothelial function by ELISA and post ischaemic reactive hyperaemia. RESULTS: The PCOS group had higher testosterone 1·2 ± 0·3 vs 0·9 ± 0·3 nmol/l (P = 0·01), HOMA-IR 2·5 ± 1·7 vs 1·7 ± 1·0 (P = 0·08), impaired glucose regulation 33·3% vs 5·3% (P = 0·02), and urinary isoprostane 16·0 ± 4·4 vs 11·8 ± 7·1 ng/ml (P = 0·04) compared to controls. Mean cIMT 0·5 ± 0·05 vs 0·48 ± 0·06 mm (P = 0·36), and basal platelet surface expression (percentage of positive cells) of P-selectin 0·52 ± 0·3 vs 0·43 ± 0·23 (P = 0·40) and fibrinogen binding 0·97 ± 0·4 vs 0·83 ± 0·3 (P = 0·48) did not significantly differ between the PCOS and control groups respectively. Furthermore, platelets sensitivity to stimulation with adenosine-5'-diphosphate or inhibition with prostacyclin, clot structure and fibrinolytic efficiency ex vivo, endothelial reactive hyperaemic index (RHI), inflammation (hsCRP) and adhesion markers (sE-selectin, sP-selectin, sVCAM-1 and sICAM-1) were not significantly different between the two groups. CONCLUSIONS: PCOS appeared not to independently increase atherothrombotic risk when matched for obesity. It is likely that any excess CV risk in young obese women with PCOS can either be attributed to obesity or is not yet apparent at this early stage of the condition. SN - 1365-2265 UR - https://www.unboundmedicine.com/medline/citation/23278130/Polycystic_ovary_syndrome_has_no_independent_effect_on_vascular_inflammatory_or_thrombotic_markers_when_matched_for_obesity_ L2 - https://doi.org/10.1111/cen.12137 DB - PRIME DP - Unbound Medicine ER -